<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460898</url>
  </required_header>
  <id_info>
    <org_study_id>A5481123</org_study_id>
    <nct_id>NCT04460898</nct_id>
  </id_info>
  <brief_title>RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.</brief_title>
  <official_title>Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This is a retrospective, observational study that will document treatment patterns and
      clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received
      Palbociclib plus Letrozole as initial endocrine-based therapy in US community oncology
      network settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Actual">June 24, 2019</completion_date>
  <primary_completion_date type="Actual">June 24, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving various cancer treatment regimens</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving each therapy sequence across lines</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving each starting dose and end dose for those on palbociclib combination therapy</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients that experienced dose adjustment</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients that discontinued therapy</measure>
    <time_frame>mBC diagnosis through end of study (assessed up to 24 months)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
    <description>HR+/HER2- metastatic breast cancer patients in the US.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include adult patients aged 18 years and older, diagnosed with HR+/HER2- mBC
        and received treatment with Palbociclib in combination with letrozole as initial
        endocrine-therapy for advanced/metastatic breast cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must meet all of the following inclusion criteria to be eligible for
             inclusion in the study:

               1. Diagnosed with locoregional recurrent or metastatic female breast cancer.

               2. Pathologically confirmed HR-positive/HER2-negative diagnosis.

               3. Received treatment with palbociclib in combination with letrozole as initial
                  endocrine-based therapy for advanced/metastatic breast cancer:

                    1. Initiated treatment with palbociclib at least 3 months following the
                       provider's first use of palbociclib following its FDA approval.

                    2. At least 1 month of follow-up (at least one visit with the provider) after
                       initiation of palbociclib.

               4. Postmenopausal (or receiving surgical or medical treatment to induce menopause)
                  at the time of initiation of palbociclib.

               5. â‰¥18 year old at initiation of palbociclib.

                  Exclusion Criteria:

          -  No exclusion criteria will be imposed for the selection of patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer United States</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A5481123</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

